-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
0 Enterprise situation analysis
As of the end of April 2022, a total of 231,990 biopharmaceutical companies have been established nationwide in 2022; among them, 62,920 new companies were established in April, an increase of -25% from the previous mon.
Table 1: Number of biopharmaceutical companies from January 2022 to April 2022
Source: Flint Creation Database
From the perspective of the geographical distribution of new enterprises, the top ten provinces in terms of number of enterprises are Guangdong, Shandong, Henan, Beijing, Jiangsu, Zhejiang, Sichuan, Fujian, Hainan and Hunan, accounting for the total number of new enterprises in the count.
From the perspective of the geographical distribution of new companies,
Table 2: Top 10 provinces and cities with newly added enterprises in April 2022
Source: Flint Creation Database
0 Analysis of industrial financing
In April 2022, a total of 78 financing events occurred in the biomedical field nationwide, with a cumulative amount of 909 billion yu.
In terms of the number of financings , the A-round and Pre-A rounds have the most financing events, 19 and 14 respective.
In terms of the number of financings , the A-round and Pre-A rounds have the most financing events, 19 and 14 respective.
Source: Flint Creation Database
In terms of financing regions, financing events this month are mainly distributed in Jiangsu Province (17 cases) and Guangdong Province (16 case.
In terms of financing regions, financing events this month are mainly distributed in Jiangsu Province (17 cases) and Guangdong Province (16 case.
Source: Flint Creation Database
In terms of financing amount, 78 financing events occurred this month , including 33 financings with a financing amount of more than 100 million yuan, 36 financings with a financing amount of 10 million yuan, and 9 financing events with an undisclosed financing amou.
In terms of financing amount, 78 financing events occurred this month ,
Figure: Distribution of financing amount in April 2022
Source: Flint Creation Database
0 Analysis of listed companies
As of the end of April 2022, there were 1,187 listed biopharmaceutical companies nationwide, and 4 new listed biopharmaceutical companies were listed in Apr.
Table 5: Top 10 biopharmaceutical companies by market value in April 2022
Source: Flint Creation Database Table 6: List of listed biopharmaceutical companies in April 2022
Source: Flint Creation Database
Compared with the previous month, Xinrui Medicine, Keju Bio, Tailing Pharmaceutical, Hongzhong Pharmaceutical, and Kintor Pharmaceutical-B have increased significant.
Table 7: The top five biopharmaceutical companies in April 2022
Source: Flint Creation Database
0 Analysis of drug clinical trials
In April 2022, a total of 249 products were approved for clinical use nationwide, a decrease of 28% compared with the previous mon.
Judging from the companies that own the clinical trials , 128 companies have been approved for clinical trials this month, of which Shanghai Henlius Biotechnology .
From the point of view of the clinical trial companies ,
From the perspective of clinical trial stages , there are 68 clinical trials in Phase I, 30 trials in Phase II, 32 trials in Phase III, and 3 trials in Phase .
From the clinical trial stage ,
Table 8: Phase III clinical trials newly launched in April
Source: Flint Creation Database
0 Analysis of drug approval
In April 2022, a total of 71 products were approved for marketing nationwide, a decrease of 46% compared with the previous mon.
This month, the State Drug Administration approved a total of 10 new drugs, including 4 category 1 new dru.
Table 9: New drugs approved by the State Drug Administration in April 2022
Source: Flint Creation Database
This month, 2 drugs were included in the priority review process by C.
Table 10: Varieties approved by CDE for priority review in April
Source: Flint Creation Database
0 Analysis of medical device approvals
In April 2022, a total of 3,288 medical devices across the country were approved for the first time, including 3,196 domestically produced devices and 92 imported devic.
In terms of product registration classification, there are 210 Class 3 medical devices, 947 Class 2 medical devices, and 2131 Class 1 medical devic.
From the perspective of the geographical distribution of the approved products, the top ten provinces with the approval of Class 3 devices are Beijing, Guangdong, Jiangsu, Shanghai, Shandong, Zhejiang, Sichuan, Fujian, Tianjin and Hun.
, accounting for 998% of the total number of newly added Class 3 device products in the count.
The top ten cities with Class 3 devices approved are Beijing, Shanghai, Shenzhen, Suzhou, Chengdu, Changzhou, Xiamen, Hangzhou, Foshan and Jinan, accounting for the total number of new Class 3 devices in the count.
69% of the amou.
Table 11: Top 10 provinces and cities with medical devices approved for the first time in April 2022
Source: Firestone Creation Database In April 2022, a total of 9 products entered the priority approval channel, and no products entered the special review and approval chann.
Table 12: Products Approved for Priority Review in April
Source: Flint Creation Database
